TIM-3 Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “TIM-3 Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TIM-3 Inhibitor: Overview
T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immunoglobulin and mucin domain-containing cell surface molecule. The protein is characterized by a common structural organization consisting of an amino-terminal immunoglobulin variable domain (V domain) with five noncanonical cysteines, a mucin stalk, a transmembrane domain and a cytoplasmic tail. TIM-3 is known to interact with four ligands, galectin-9, phosphatidylserie (PtdSer), CEACAM-1and HMGB1 (high mobility group box-1). Tim-3 is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Various preclinical data support the therapeutic modulation of TIM3 in multiple disease contexts including autoimmunity, infection, and cancer. The blocking of Tim-3 and PD-1 together can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients.
Report Highlights
This segment of the TIM-3 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIM-3 Inhibitor Emerging Drugs
Further product details are provided in the report……..
TIM-3 Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different TIM-3 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
TIM-3 Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIM-3 Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIM-3 Inhibitor drugs.
TIM-3 Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TIM-3 Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TIM-3 Inhibitor: Overview
T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immunoglobulin and mucin domain-containing cell surface molecule. The protein is characterized by a common structural organization consisting of an amino-terminal immunoglobulin variable domain (V domain) with five noncanonical cysteines, a mucin stalk, a transmembrane domain and a cytoplasmic tail. TIM-3 is known to interact with four ligands, galectin-9, phosphatidylserie (PtdSer), CEACAM-1and HMGB1 (high mobility group box-1). Tim-3 is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Various preclinical data support the therapeutic modulation of TIM3 in multiple disease contexts including autoimmunity, infection, and cancer. The blocking of Tim-3 and PD-1 together can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TIM-3 Inhibitor R&D. The therapies under development are focused on novel approaches for TIM-3 Inhibitor.
This segment of the TIM-3 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIM-3 Inhibitor Emerging Drugs
- Cobolimab: GlaxoSmithKline
- BMS-986258: Bristol-Myers Squibb
Further product details are provided in the report……..
TIM-3 Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different TIM-3 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TIM-3 Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TIM-3 Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIM-3 Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIM-3 Inhibitor drugs.
TIM-3 Inhibitor Report Insights
- TIM-3 Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TIM-3 Inhibitor drugs?
- How many TIM-3 Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for TIM-3 Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIM-3 Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TIM-3 Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novarits
- GlaxoSmithKline
- Roche
- Incyte Corporation
- Bristol-Myers Squibb
- Novartis
- Interprotein
- TrueBinding
- Celgene
- Sutro Biopharma
- Neologics Bioscience
- Symphogen
- Sabatolimab
- Cobolimab
- RG-7769
- INCAGN 02390
- BMS 986258
- MAS-825
- Research program: anticancer peptide therapeutics
- Anti-T-cell immunoglobulin and mucin domain-3 monoclonal antibody
- Research program: antibody based therapeutics
- NB 002
- Sym-023
Introduction
Executive Summary
TIM-3 Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIM-3 Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TIM-3 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TIM-3 Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novarits Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS 986258: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Sym 023: Symphogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NB 002: Neologics Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIM-3 Inhibitor Key Companies
TIM-3 Inhibitor Key Products
TIM-3 Inhibitor- Unmet Needs
TIM-3 Inhibitor- Market Drivers and Barriers
TIM-3 Inhibitor- Future Perspectives and Conclusion
TIM-3 Inhibitor Analyst Views
TIM-3 Inhibitor Key Companies
Appendix
Executive Summary
TIM-3 Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TIM-3 Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TIM-3 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TIM-3 Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novarits Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS 986258: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Sym 023: Symphogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NB 002: Neologics Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TIM-3 Inhibitor Key Companies
TIM-3 Inhibitor Key Products
TIM-3 Inhibitor- Unmet Needs
TIM-3 Inhibitor- Market Drivers and Barriers
TIM-3 Inhibitor- Future Perspectives and Conclusion
TIM-3 Inhibitor Analyst Views
TIM-3 Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for TIM-3 Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for TIM-3 Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for TIM-3 Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for TIM-3 Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
